BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33782411)

  • 1. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
    Shang M; Yang H; Yang R; Chen T; Fu Y; Li Y; Fang X; Zhang K; Zhang J; Li H; Cao X; Gu J; Xiao J; Zhang Q; Liu X; Yu Q; Wang T
    Nat Commun; 2021 Mar; 12(1):1940. PubMed ID: 33782411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    Ju HQ; Lu YX; Chen DL; Zuo ZX; Liu ZX; Wu QN; Mo HY; Wang ZX; Wang DS; Pu HY; Zeng ZL; Li B; Xie D; Huang P; Hung MC; Chiao PJ; Xu RH
    J Natl Cancer Inst; 2019 Jun; 111(6):584-596. PubMed ID: 30534944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes.
    Yu C; Yang L; Cai M; Zhou F; Xiao S; Li Y; Wan T; Cheng D; Wang L; Zhao C; Huang X
    J Cell Mol Med; 2020 Jan; 24(2):1568-1577. PubMed ID: 31778025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling.
    Shi Y; Xu Y; Yao J; Yan C; Su H; Zhang X; Chen E; Ying K
    J Cell Mol Med; 2021 Jul; 25(14):7013-7027. PubMed ID: 34121323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer.
    Liu X; Liu S; Piao C; Zhang Z; Zhang X; Jiang Y; Kong C
    Cancer Sci; 2021 Dec; 112(12):4909-4919. PubMed ID: 34632667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
    Lin H; Huang B; Wang H; Liu X; Hong Y; Qiu S; Zheng J
    Cell Physiol Biochem; 2018; 51(2):991-1000. PubMed ID: 30466107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-33a-5p suppresses colorectal cancer cell growth by inhibiting MTHFD2.
    Yan Y; Zhang D; Lei T; Zhao C; Han J; Cui J; Wang Y
    Clin Exp Pharmacol Physiol; 2019 Oct; 46(10):928-936. PubMed ID: 31209892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage.
    Li G; Wu J; Li L; Jiang P
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATF4/MYC Regulates MTHFD2 to Promote NSCLC Progression by Mediating Redox Homeostasis.
    Gao Y; Feng L; Zhang L; Geng J; Zhang E
    Dis Markers; 2022; 2022():7527996. PubMed ID: 36051358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of MTHFD2 is associated with clinicopathological characteristics and poor survival in ovarian cancer, possibly by regulating MOB1A signaling.
    Cui X; Su H; Yang J; Wu X; Huo K; Jing X; Zhang S
    J Ovarian Res; 2022 Feb; 15(1):23. PubMed ID: 35135596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer.
    Lee J; Chen X; Wang Y; Nishimura T; Li M; Ishikawa S; Daikoku T; Kawai J; Tojo A; Gotoh N
    Biochem Biophys Res Commun; 2021 Dec; 584():7-14. PubMed ID: 34753066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
    Nishimura T; Nakata A; Chen X; Nishi K; Meguro-Horike M; Sasaki S; Kita K; Horike SI; Saitoh K; Kato K; Igarashi K; Murayama T; Kohno S; Takahashi C; Mukaida N; Yano S; Soga T; Tojo A; Gotoh N
    Oncogene; 2019 Apr; 38(14):2464-2481. PubMed ID: 30532069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-92a Inhibits Proliferation and Induces Apoptosis by Regulating Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) Expression in Acute Myeloid Leukemia.
    Gu Y; Si J; Xiao X; Tian Y; Yang S
    Oncol Res; 2017 Aug; 25(7):1069-1079. PubMed ID: 28059050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Expression of Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2) in Esophageal Squamous Cell Carcinoma and its Clinical Prognostic Significance.
    He H; Li PC; Jia W; Hu B; Ji CS
    Med Sci Monit; 2020 Feb; 26():e920259. PubMed ID: 32088725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate enzyme MTHFD2 links one-carbon metabolism to unfolded protein response in glioblastoma.
    Zhu Z; Kiang KM; Li N; Liu J; Zhang P; Jin L; He X; Zhang S; Leung GK
    Cancer Lett; 2022 Nov; 549():215903. PubMed ID: 36089117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress.
    Bonagas N; Gustafsson NMS; Henriksson M; Marttila P; Gustafsson R; Wiita E; Borhade S; Green AC; Vallin KSA; Sarno A; Svensson R; Göktürk C; Pham T; Jemth AS; Loseva O; Cookson V; Kiweler N; Sandberg L; Rasti A; Unterlass JE; Haraldsson M; Andersson Y; Scaletti ER; Bengtsson C; Paulin CBJ; Sanjiv K; Abdurakhmanov E; Pudelko L; Kunz B; Desroses M; Iliev P; Färnegårdh K; Krämer A; Garg N; Michel M; Häggblad S; Jarvius M; Kalderén C; Jensen AB; Almlöf I; Karsten S; Zhang SM; Häggblad M; Eriksson A; Liu J; Glinghammar B; Nekhotiaeva N; Klingegård F; Koolmeister T; Martens U; Llona-Minguez S; Moulson R; Nordström H; Parrow V; Dahllund L; Sjöberg B; Vargas IL; Vo DD; Wannberg J; Knapp S; Krokan HE; Arvidsson PI; Scobie M; Meiser J; Stenmark P; Berglund UW; Homan EJ; Helleday T
    Nat Cancer; 2022 Feb; 3(2):156-172. PubMed ID: 35228749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xanthine Derivatives Reveal an Allosteric Binding Site in Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2).
    Lee LC; Peng YH; Chang HH; Hsu T; Lu CT; Huang CH; Hsueh CC; Kung FC; Kuo CC; Jiaang WT; Wu SY
    J Med Chem; 2021 Aug; 64(15):11288-11301. PubMed ID: 34337952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell.
    Wan X; Wang C; Huang Z; Zhou D; Xiang S; Qi Q; Chen X; Arbely E; Liu CY; Du P; Yu W
    Cell Death Dis; 2020 Aug; 11(8):649. PubMed ID: 32811824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer.
    Nilsson R; Jain M; Madhusudhan N; Sheppard NG; Strittmatter L; Kampf C; Huang J; Asplund A; Mootha VK
    Nat Commun; 2014; 5():3128. PubMed ID: 24451681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.